You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
9 November 2026 - French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday announced positive results from two Phase 2 trials of S4V2, its tetravalent bioconjugate vaccine candidate targeting shigellosis.The studies demonstrated...
9 November 2026 - Diagnostic company Photocure ASA (OSE: PHO) confirmed on Monday that the anticipated Medicare coverage timeline for its AssureMDx bladder cancer test remains aligned with its original acquisition assumptions, following a newly publi...
9 November 2026 - Biotechnology company Halozyme Therapeutics Inc (Nasdaq:HALO) announced on Friday that Johnson & Johnson (NYSE:JNJ) was granted accelerated approval from the US Food and Drug Administration (FDA) for RYBREVANT FASPRO (amivantama...
9 November 2026 - Commercial-stage biopharmaceutical company Bio-Thera Solutions Ltd (SHA:688177) announced on Monday that China's National Medical Products Administration (NMPA) has approved its marketing authorisation for BAT2506, a golimumab ...
9 November 2026 - Clinical-stage biotechnology company GlycoNex Inc (TPEx:4168) announced on Sunday that a marketing authorisation application for SPD8, its denosumab biosimilar candidate co-developed with Mitsubishi Gas Chemical (MGC), has been subm...
6 November 2026 - Commercial-stage biotech company Antengene Corporation Limited (SEHK:6996) announced on Thursday that the first patient has been dosed in China in the Phase I ATTRACT study evaluating ATG-201, Antengene's proprietary CD19 x CD3...
6 November 2026 - Chinese pharmaceutical company Akeso Inc (HKEX:9926) announced on Thursday that results from a Phase II clinical study evaluating its first-in-class PD-1/VEGF bispecific antibody ivonescimab in the perioperative treatment of resecta...